POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC
POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC
Active, not recruiting · NCT05782361 · Registry updated 2026-04-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 1 | 2026-04-24 | NCT05782361 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Institute of Cancer Research, United Kingdom | 59 |
| Merck KGaA, Darmstadt, Germany | 31 |
| Merck Sharp & Dohme LLC | 650 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| DDU, Royal Marsden Hospital NHS Foundation Trust | Sutton | United Kingdom | 1 |
| Lung Unit, Royal Marsden Hospital NHS Foundation Trust | London | United Kingdom | 1 |
| The Christie NHS Foundation Trust | Manchester | United Kingdom | 113 |
| University College London Hospitals NHS Foundation Trust | London | United Kingdom | 11 |